GlassScriptPhysician profile
Nikita Varshneya
NPI 1275551103
$5,340.76
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $1,211 · 2021: $1,329 · 2022: $1,210 · 2023: $386 · 2024: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $744.26 | 2019-2022 | |
| Abbott Laboratories | $449.20 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $411.84 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $387.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $350.61 | 2019-2023 | Xarelto |
| Daiichi Sankyo INC. | $328.68 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $292.46 | 2019-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $289.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.64 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $170.42 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $139.97 | 2019-2022 | |
| Esperion Therapeutics, INC. | $132.73 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $131.19 | 2019-2023 | |
| Irhythm Technologies, INC. | $129.81 | 2022 | |
| Pfizer INC. | $119.71 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikita Varshneya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.